Sutro Biopharma, Inc.
STRO
$7.30
-$0.72-8.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -34.36% | -38.31% | -56.88% | -59.64% | 230.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.36% | -38.31% | -56.88% | -59.64% | 230.90% |
| Cost of Revenue | -805.80% | -1,559.17% | -72.55% | -448.22% | -92.65% |
| Gross Profit | 30.45% | -1.77% | -39.19% | -27.24% | 222.56% |
| SG&A Expenses | -26.39% | -17.82% | -18.04% | -22.58% | -7.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.77% | -1.98% | 14.77% | 23.66% | 26.36% |
| Operating Income | -5.01% | -56.00% | -121.30% | -167.09% | 28.41% |
| Income Before Tax | -98.29% | -93.23% | -149.95% | -154.06% | 36.41% |
| Income Tax Expenses | -85.22% | -86.76% | -86.72% | -87.01% | 563.10% |
| Earnings from Continuing Operations | -74.88% | -67.70% | -113.31% | -112.99% | 28.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.88% | -67.70% | -113.31% | -112.99% | 28.12% |
| EBIT | -5.01% | -56.00% | -121.30% | -167.09% | 28.41% |
| EBITDA | -4.90% | -59.51% | -129.62% | -180.41% | 29.75% |
| EPS Basic | -60.02% | -36.94% | -57.60% | -67.78% | 44.21% |
| Normalized Basic EPS | -4.45% | -27.59% | -57.24% | -104.78% | 40.20% |
| EPS Diluted | -60.02% | -36.94% | -57.60% | -67.78% | 44.21% |
| Normalized Diluted EPS | -4.45% | -27.59% | -57.24% | -104.78% | 40.20% |
| Average Basic Shares Outstanding | 17.28% | 25.73% | 35.14% | 27.68% | 20.67% |
| Average Diluted Shares Outstanding | 17.28% | 25.73% | 35.14% | 27.68% | 20.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |